In recent years, Taiwan\u2019s biotechnology and medical sectors have experienced significant growth, closely aligned with global scientific advancements. Research and development efforts continue to expand in advanced therapeutic modalities, including cell and gene therapies and nucleic acid\u2013based medicines, collectively referred to as Advanced Therapy Medicinal Products (ATMPs).<\/p>\n\n\n\n
As these innovative therapies play a critical role in the treatment of rare diseases, cancer, and other serious conditions, product quality and patient safety have become central pillars of regulatory review. Across all stages\u2014research and development, clinical trials, and final product release\u2014endotoxin and mycoplasma testing are recognized as indispensable quality control requirements for cell therapy products.<\/p>\n\n\n\n
In accordance with international regulatory frameworks such as USP, EP, JP, ICH guidelines, and the PIC\/S GMP quality system, manufacturers of cell-based and biological products must demonstrate that raw materials, reagents, and finished products meet stringent microbiological safety standards to ensure clinical safety, consistency, and reliability.<\/p>\n\n\n\n
Endotoxins are lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria. Even when viable bacteria have been eliminated, endotoxins may persist in manufacturing environments, raw materials, or water systems. In humans, extremely low levels of endotoxin exposure can induce fever, hypotension, and systemic inflammatory responses, posing a significant risk\u2014particularly for patients receiving cell therapy products.<\/p>\n\n\n\n
As a result, endotoxin testing is universally mandated by regulatory authorities as a critical release criterion for cell-based medicinal products.<\/p>\n\n\n\n
Mycoplasma are among the smallest self-replicating microorganisms and lack a cell wall, enabling them to pass through standard filtration systems and evade detection by conventional culture methods. More importantly, mycoplasma contamination can adversely affect cell growth, metabolism, gene expression, and immune responses, potentially leading to compromised research data and reduced clinical efficacy or safety.<\/p>\n\n\n\n
Consequently, USP <63>, EP 2.6.7, and multiple cell therapy\u2013related regulatory guidelines designate mycoplasma testing as a mandatory requirement prior to product release.<\/p>\n\n\n\n
In the field of cell therapy testing, method sensitivity and suitability for complex biological samples are fundamental service requirements. Even when internationally accepted methods are employed, insufficient quality management systems or the absence of third-party accreditation may raise concerns regarding data credibility and regulatory acceptance.<\/p>\n\n\n\n
UniPharma MB Lab. conducts endotoxin and mycoplasma testing in accordance with the Taiwan Pharmacopoeia (9th Edition) guidelines. Testing is performed on both raw materials and finished products. All laboratory procedures, data interpretation, and reporting strictly follow ISO\/IEC 17025\u2013based Standard Operating Procedures (SOPs), ensuring compliance with regulatory limits and safeguarding patient safety.<\/p>\n\n\n\n
Category<\/strong><\/td>| Endotoxin<\/strong><\/td> | Mycoplasma<\/strong><\/td><\/tr> | Applicable Products<\/strong><\/td> | Cell-based products (including cell-derived biologics, cell culture supernatants, and injectable products)<\/td><\/tr> | Regulatory References<\/strong><\/td> | Taiwan Pharmacopoeia (9th Ed.) Sections 3085, 3086<\/td> | Taiwan Pharmacopoeia (9th Ed.) Sections 5063, 5064, 5326<\/td><\/tr> | Method Description | & Advantages<\/strong><\/td> Kinetic Turbidimetric Limulus Amebocyte Lysate (LAL) Assay | <\/strong>The laboratory employs pharmacopoeial kinetic turbidimetric methods (KT), performed by trained professionals with precise sample pretreatment and continuous kinetic monitoring using an ELISA reader. Compared with traditional gel-clot methods, the KT method offers a wider quantitative range and stronger interference resistance, allowing more accurate endotoxin quantification in cell therapy products.<\/td> Real-time PCR Mycoplasma Detection<\/strong> | High-performance nucleic acid amplification technology is applied to overcome the time-consuming nature and contamination risks of traditional methods, enabling rapid release assessment. PCR-based detection significantly shortens testing time, making it particularly suitable for cell therapy products with limited shelf life and supporting efficient manufacturing decisions.<\/td><\/tr> Minimum Sample Volume<\/strong><\/td> | \u2265 0.5 mL<\/td> | \u2265 1 mL<\/td><\/tr> | Sensitivity<\/strong><\/td> | 0.01 EU\/mL<\/td> | 10 CFU\/mL<\/td><\/tr> | Turnaround Time<\/strong><\/td> | Standard: 7 business days | Expedited: 3 business days<\/td> Standard: 7 business days | Expedited: 3 business days<\/td><\/tr> Deliverables<\/strong><\/td> | Endotoxin Test Report<\/td> | Mycoplasma Test Report<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n | A Regulatory-Driven Approach: Advancing Toward TAF Accreditation for Long-Term Trust<\/strong><\/h2>\n\n\n\nAchieving TAF accreditation signifies that a laboratory has successfully passed rigorous third-party assessments in the following areas:<\/p>\n\n\n\n
|